Targeting Undruggable Protein KRAS for Cancer Therapy: Novel Opportunities and Challenges

Overview

Journal Future Med Chem

Specialties Chemistry
Pharmacy

Date 2024 Dec 23

PMID 39713985

Authors

Xin Yang

Xiang Li

Yue-Lin Zhang

Sheng-Nan Zhang

Miao Zhang

Chong Sun

Li Yang

Hong-Min Liu

Shuo Yuan

Affiliations

Soon will be listed here.

References

Singhal A, Li B, OReilly E . Targeting KRAS in cancer. Nat Med. 2024; 30(4):969-983. PMC: 11845254. DOI: 10.1038/s41591-024-02903-0. View

Pulciani S, Santos E, Long L, Sorrentino V, Barbacid M . ras gene Amplification and malignant transformation. Mol Cell Biol. 1985; 5(10):2836-41. PMC: 367023. DOI: 10.1128/mcb.5.10.2836-2841.1985. View

Hofmann M, Gerlach D, Misale S, Petronczki M, Kraut N . Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discov. 2022; 12(4):924-937. PMC: 9394389. DOI: 10.1158/2159-8290.CD-21-1331. View

Ma X, Sloman D, Duggal R, Anderson K, Ballard J, Bharathan I . Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS Inhibitor. J Med Chem. 2024; 67(13):11024-11052. DOI: 10.1021/acs.jmedchem.4c00572. View

Canon J, Rex K, Saiki A, Mohr C, Cooke K, Bagal D . The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019; 575(7781):217-223. DOI: 10.1038/s41586-019-1694-1. View

Dillon M, Lopez A, Lin E, Sales D, Perets R, Jain P . Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Cancers (Basel). 2021; 13(20). PMC: 8534156. DOI: 10.3390/cancers13205059. View

Liang F, Kang Z, Sun X, Chen J, Duan X, He H . Inhibition mechanism of MRTX1133 on KRAS: a molecular dynamics simulation and Markov state model study. J Comput Aided Mol Des. 2023; 37(3):157-166. DOI: 10.1007/s10822-023-00498-1. View

Popow J, Farnaby W, Gollner A, Kofink C, Fischer G, Wurm M . Targeting cancer with small-molecule pan-KRAS degraders. Science. 2024; 385(6715):1338-1347. DOI: 10.1126/science.adm8684. View

Ostrem J, Peters U, Sos M, Wells J, Shokat K . K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013; 503(7477):548-51. PMC: 4274051. DOI: 10.1038/nature12796. View

10.

Rubinson D, Tanaka N, Fece de la Cruz F, Kapner K, Rosenthal M, Norden B . Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers. Cancer Discov. 2024; 14(5):727-736. PMC: 11061598. DOI: 10.1158/2159-8290.CD-23-1138. View

11.

Lu X, Jin J, Wu Y, Liu X, Liang X, Lin J . Progress in RAS-targeted therapeutic strategies: From small molecule inhibitors to proteolysis targeting chimeras. Med Res Rev. 2023; 44(2):812-832. DOI: 10.1002/med.21993. View

12.

Yaeger R, Weiss J, Pelster M, Spira A, Barve M, Ou S . Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated G12C. N Engl J Med. 2022; 388(1):44-54. PMC: 9908297. DOI: 10.1056/NEJMoa2212419. View

13.

Fakih M, Salvatore L, Esaki T, Modest D, Lopez-Bravo D, Taieb J . Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated G12C. N Engl J Med. 2023; 389(23):2125-2139. DOI: 10.1056/NEJMoa2308795. View

14.

Kettle J, Bagal S, Barratt D, Bodnarchuk M, Boyd S, Braybrooke E . Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS with Demonstrable CNS Penetration. J Med Chem. 2023; 66(13):9147-9160. DOI: 10.1021/acs.jmedchem.3c00746. View

15.

Mukhopadhyay S, Huang H, Lin Z, Ranieri M, Li S, Sahu S . Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy. Cancer Res. 2023; 83(24):4095-4111. PMC: 10841254. DOI: 10.1158/0008-5472.CAN-23-2729. View

16.

Manchado E, Weissmueller S, Morris 4th J, Chen C, Wullenkord R, Lujambio A . A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016; 534(7609):647-51. PMC: 4939262. DOI: 10.1038/nature18600. View

17.

Zheng G, Tseng L, Haley L, Ibrahim J, Bynum J, Xian R . Clinical validation of coexisting driver mutations in colorectal cancers. Hum Pathol. 2018; 86:12-20. PMC: 6467705. DOI: 10.1016/j.humpath.2018.11.014. View

18.

Suzuki S, Yonesaka K, Teramura T, Takehara T, Kato R, Sakai H . KRAS Inhibitor Resistance in -Amplified Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms. Clin Cancer Res. 2021; 27(20):5697-5707. DOI: 10.1158/1078-0432.CCR-21-0856. View

19.

Coley A, Ward A, Keeton A, Chen X, Maxuitenko Y, Prakash A . Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone. Adv Cancer Res. 2022; 153:131-168. DOI: 10.1016/bs.acr.2021.07.009. View

20.

Xiao X, Feng J, Ma J, Xia X, Liu X, Zhang J . Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRAS Inhibitors. J Med Chem. 2023; 66(22):15524-15549. DOI: 10.1021/acs.jmedchem.3c01724. View